Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents

Journal of Infectious Diseases

Volumn 173, Issue 4, 1996, Pages 1009-1013

  Mitchell, Leslie Ann ^a   Ochnio, Jan J ^b   Glover, Candice ^b   Lee, Ashley Y ^b   Ho, Margaret K L ^b   Bell, Alison ^b  

^a Vaccine Evaluation Center   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

AGE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CHILD; CONTROLLED STUDY; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; SEROTYPE; SEX; VACCINATION;

EID: 0029935881     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.4.1009     Document Type: Article

References (16)

1. Zangwill KM, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994;169:847-52.
2. Carlone GM, Frasch CE, Siber GR, et al. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular antibody measured by using an enzyme-linked immunosorbent assay. J Clin Microbiol 1992;30:154-9.
3. Gold R, Lepow ML, Goldschneider I, et al. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975;56:1536-47.
4. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129:1307-26.
5. Goldschneider I, Gotschlich E, Artenstein M. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969;129:1327-48.
6. Lepow ML, Goldschneider I, Gold R, et al. Persistence of antibody following immunization of children with group A and group C meningococcal polysaccharide. Pediatrics 1977;60:673-9.
7. Peltola H, Makela PH, Kahty H, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977;297:686-91.
8. Gold R. Immunogenicity of meningococcal polysaccharide in man. In: Rudback J, Baker D, eds. Immunology of bacterial polysaccharides. New York: Elsevier/North Holland, 1979:121-51.
9. Griffiss JM, Bertram M. Immunoepidemiology of meningococcal disease in military recruits. II. Blocking of serum bactericidal activity by circulating IgA early in the course of invasive disease. J Infect Dis 1977;136:733-9.
10. Kayhty H, Jousimes-Somer H, Peltola H, Makela H. Antibody response to capsular polysaccharide of groups A and C Neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease. J Infect Dis 1981;143:32-41.
11. Halstenson A, Hanenberg B, Froholm LO, et al. Human opsonins to meningococci after vaccination. Infect Immun 1984;46:673-6.
12. Rubenstein LJ, Stein KE. Murine response to the Neisseria meningitidis group C polysaccharide. II. Specificity. J Immunol 1988;141:4357-62.
13. Gold R, Lepow ML, Goldschneider I, et al. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines during the first 6 years of life: prospects for routine immunization of infants and children. J Infect Dis 1979;140:690-7.
14. Gold R, Artenstein MS. Meningococcal infections. II. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ 1971;45:279-82.
15. Anderson EL, Bowers T, Mink CM, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccines in adults. Infect Immun 1994;62:3391-5.
16. Twumasi PA Jr, Kumah S, Leach A, et al. A trial of group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995;171:632-8.